The data showed the strong anti-tumor and anti-metastatic effects in various epithelial tumor cells by the binding of AMC303 to the extracellular domain of CD44v6. The isoform CD44v6 of the CD44 family of transmembrane glycoproteins has been shown to play a major role in tumor growth and metastasis.
This study has shown that blocking CD44v6, an essential co-receptor for the receptor tyrosine kinases VEGFR-2, c-MET, and RON, interferes with several key steps in tumor progression and metastasis including epithelial-mesenchymal-transition (EMT), cell migration, and invasion.
AMC303, amcure's lead compound, is being developed as a potential treatment for patients with advanced and metastatic epithelial tumors, e.g. pancreatic cancer, head and neck cancer, gastric cancer, colorectal cancer, breast cancer, and lung cancer. It has demonstrated strong effects in various in vitro and in vivo assays.
amcure GmbH, a spin-off from the Karlsruhe Institute of Technology established in 2012, develops peptide-based compounds for the treatment of highly metastatic forms of cancer.
amcure's most advanced development candidate, AMC303, has entered clinical development and has demonstrated in in vivo animal proof-of-concept studies a high efficacy against different types of epithelial cancers. amcure is supported by a grant from the German Federal Ministry of Education and Research.
AstraZeneca launches Phase III THARROS trial for BREZTRI in COPD to assess cardiopulmonary outcomes
Merck finalises acquisition of Harpoon Therapeutics Inc
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
Nuvalent's NVL-520 receives FDA breakthrough therapy designation
Dassault Systèmes enhances patient care with virtual twin experience at Paris hospital
Pulmonx initiates CONVERT II trial for AeriSeal System in COPD treatment
Priority Review of Dupixent underway by FDA for COPD treatment
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
AstraZeneca reports positive resultsfor Tagrisso in Stage III lung cancer trial
AstraZeneca announces US acceptance of BLA for datopotamab deruxtecan to treat lung cancer
Erasca agrees clinical trial deal with Novartis to study naporafenib in combination with trametinib
FDA accepts Bristol Myers Squibb's Augtyro application for Priority Review